General sample: diagnostic parameters of bronchodilator reversibility cut-off points for current doctor-diagnosed asthma and asthma–COPD overlap (ACO)
| Sensitivity % (95% CI) | Specificity % (95% CI) | Positive predictive value % (95% CI) | Negative predictive value % (95% CI) | Positive likelihood ratio (95% CI) | Negative likelihood ratio (95% CI) | Diagnostic OR (95% CI) | |
| Asthma | |||||||
| ΔFEV1 (mL) ULN# | 16 (11–23) | 92 (91–93) | 11 (7–16) | 95 (94–96) | 2.09 (1.42–3.09) | 0.91 (0.85–0.98) | 2.30 (1.45–3.65) |
| ΔFEV1% of initial FEV1 ULN¶ | 20 (14–27) | 92 (91–93) | 13 (9–19) | 95 (94–96) | 2.58 (1.81–3.68) | 0.87 (0.80–0.94) | 2.97 (1.93–4.57) |
| ΔFEV1% of predicted FEV1 ULN+ | 15 (10–21) | 94 (93–95) | 13 (8–19) | 95 (94–96) | 2.40 (1.58–3.63) | 0.91 (0.85–0.97) | 2.64 (1.63–4.27) |
| ΔFEV1 12% of initial+200 mL | 9 (6–15) | 97 (96–98) | 16 (9–26) | 95 (94–96) | 3.26 (1.89–5.65) | 0.93 (0.89–0.98) | 3.50 (1.92–6.37) |
| ΔFEV1 15% of initial+400 mL | 5 (2–9) | 99 (99–99) | 23 (10–41) | 95 (94–95) | 4.83 (2.12–11.02) | 0.96 (0.93–1.00) | 5.02 (2.13–11.85) |
| ACO | |||||||
| ΔFEV1 (mL) ULN# | 42 (28–57) | 92 (91–93) | 9 (5–13) | 99 (98–99) | 5.40 (3.70–7.88) | 0.63 (0.49–0.81) | 8.56 (4.59–15.98) |
| ΔFEV1% of initial FEV1 ULN¶ | 60 (46–74) | 92 (91–93) | 12 (8–17) | 99 (99–100) | 7.96 (6.03–10.52) | 0.43 (0.30–0.62) | 18.62 (9.92–34.93) |
| ΔFEV1% of predicted FEV1 ULN+ | 40 (26–54) | 94 (93–95) | 10 (6–16) | 99 (98–99) | 6.37 (4.27–9.51) | 0.65 (0.51–0.82) | 9.89 (5.25–18.62) |
| ΔFEV1 12% of initial+200 mL | 47 (33–61) | 97 (96–98) | 22 (14–32) | 99 (99–99) | 16.05 (10.82–23.80) | 0.55 (0.42–0.73) | 29.14 (15.30–55.48) |
| ΔFEV1 15% of initial+400 mL | 12 (5–24) | 99 (99–99) | 17 (6–36) | 98 (98–99) | 11.87 (4.75–29.64) | 0.89 (0.80–1.00) | 13.30 (4.82–36.72) |
ΔFEV1: change in forced expiratory volume in 1 s; ULN: upper limit of normal. #: 280 mL; ¶: 9.2%; +: 8.8%.